IP Library Granted Patent US 8,241,886
Granted Patent B2
US 8,241,886 · App. 12/733,920 · Granted Aug 14, 2012

Formulations for preservation of rotavirus

Assignee: Aridis Pharmaceuticals
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,241,886
App. No.
12/733,920
Granted
Aug 14, 2012
Kind
B2
Abstract

This invention provides formulations and methods for stabilizing viruses in liquid and dried formulations. In particular, formulations are provided including Zn 2 + cations that stabilize the viability of Rotaviruses. Methods of vaccination include neutralization of gastric contents and administration of the vaccine formulations of the invention.

Claims (39)

1. A liquid vaccine formulation comprising:

at least one strain of rotavirus at a titer ranging from about 1×10 5 to about 1×10 8 pfu/mL;

a sugar at a concentration ranging from about 10% to about 60% (w/v);

a phosphate buffer ranging in concentration from about 10 mM to about 2 M;

a carboxylate ranging in concentration from about 50 mM to about 2 M; and,

Zn 2+ in a concentration ranging from 1 to 6 mM.

2. The formulation of claim 1 , further comprising Ca 2+ in a concentration ranging from 1 to 10 mM.

3. The formulation of claim 1 , further comprising from about 0.5% to about 5% of gelatin or from about 0.001% to about 2% of a non ionic surfactant.

4. The formulation of claim 1 , wherein the carboxylate is selected from the group consisting of: succinate, citrate, fumarate, tartarate, maleate and lactate.

5. The formulation according to claim 1 , wherein the sugar is selected from the group consisting of: sucrose, mannitol, lactose, sorbitol, dextrose, fucose, trehalose, polyaspartic acid, inositol hexaphosphate (phytic acid), sialic acid and N-acetylneuraminic acid-lactose.

6. The liquid vaccine formulation of claim 1 , further comprising at least one diluent selected from the group consisting of: a tissue culture medium, saline and water.

7. The formulation of claim 1 , wherein the concentration of sugar is between about 20% to about 40%; the concentration of phosphate is between about 0.05 to about 0.3 M; and said at least one carboxylate is a citrate or a succinate at a concentration between about 0.05 M and about 0.7 M.

8. The formulation according to claim 1 , wherein a pH of the formulation ranges from about pH 5.0 to about pH 8.0.

9. The formulation according to claim 1 , wherein the phosphate is selected from the group consisting of: a monophosphate, a polyphosphate and a phosphorylated compound.

10. The formulation according to claim 9 , wherein the phosphorylated compounds are phosphorylated sugars or phosphorylated sugar acids.

11. The formulation according to claim 1 , wherein the non ionic surfactant is selected from the group consisting of: a polysorbate, a polyoxyethylene alkyl ether, a nonaethylene glycol octylphenyl ether, a hepatethylene glycol octylphenyl ether, a sorbitan trioleate, and a polyoxyethylene-polyoxypropylene block copolymer.

12. The formulation according to claim 1 , wherein the surfactant concentration ranges from about 0.005% to about 0.1%.

13. A liquid vaccine formulation comprising:

at least one strain of rotavirus at a titer ranging from about 1×10 5 to about 1×10 7 pfu/mL;

a sugar at a concentration ranging from about 15% to about 30% (w/v);

a phosphate buffer ranging in concentration from about 40 mM to about 100 mM;

a carboxylate ranging in concentration from about 40 mM to about 300 mM: and,

Zn 2+ in a concentration ranging from 1 to 6 mM;

wherein the formulation pH is about pH 6.0 to about pH 6.5.

14. A method of stabilizing a rotavirus, the method comprising:

cultivating the rotavirus; and,

formulating the rotavirus in a liquid formulation comprising:

the rotavirus at a titer ranging from about 1×10 5 to about 1×10 8 pfu/mL;

a sugar at a concentration ranging from about 5% to about 40% (w/v);

a pH buffer ranging in concentration from about 10 mM to about 2 M at a pH ranging from about pH 5 to about pH 7; and,

Zn 2+ in a concentration ranging from 1 to 6 mM.

15. The method of claim 14 , wherein the formulation further comprises Ca 2+ at a concentration ranging 1 to 10 mM.

16. The method of claim 14 , wherein the formulation further comprises from about 0.5% to about 5% of gelatin or from about 0.001% to about 2% of an non ionic surfactant.

17. The method of claim 14 , wherein the formulation further comprises from about 0.05 M to about 2 M of a carboxylate.

18. The method of claim 14 , wherein the sugar is selected from the group consisting of: sucrose, mannitol, lactose, sorbitol, dextrose, fucose, trehalose, polyaspartic acid, inositol hexaphosphate (phytic acid), sialic acid and N-acetylneuraminic acid-lactose.

19. The method of claim 14 , wherein the buffer comprises a phosphate buffer at a pH ranging from pH 5 to pH 8.

20. The method of claim 14 , wherein the Zn 2+ concentration is about 4 mM.

21. The method of claim 14 , further comprising the step of lyophilizing the liquid formulation.

22. The method of claim 14 , further comprising the step of spray drying the liquid formulation.

Assignments (2)
SECURITY INTEREST Recorded Jun 21, 2023
From: ARIDIS PHARMACEUTICALS, INC.; ARIDIS BIOPHARMACEUTICALS, LLC; ARIDIS PHARMACEUTICALS, C.V.
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 064020/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2011
From: TRUONG-LE, VU; YEE, LUISA; LECHUGA-BALLESTEROS, DAVID; OHTAKE, SATOSHI
To: ARIDIS PHARMACEUTICALS
Reel/Frame 027371/0508 →
Continuity (2)
Provisional Application 60995291 · Sep 25, 2007
Related Publication 20100226939A1 · Sep 9, 2010